(Reuters) - The St. Paul, Minnesota-based cardiovascular device maker,
which raised its 2007 earnings forecast after a solid first
quarter, again lifted its forecast, calling for third-quarter
earnings per diluted share of 44 to 45 cents and full year
earnings of $1.74 to $1.78, excluding the charge for the patent
settlement.
St. Jude, which competes most directly with Medtronic Inc.
and Boston Scientific Corp. , posted a net
profit of $135 million, or 39 cents per diluted share, compared
with a profit of $141 million, or 38 cents, a year ago.
Read more at Reuters.com Market News
which raised its 2007 earnings forecast after a solid first
quarter, again lifted its forecast, calling for third-quarter
earnings per diluted share of 44 to 45 cents and full year
earnings of $1.74 to $1.78, excluding the charge for the patent
settlement.
St. Jude, which competes most directly with Medtronic Inc.
and Boston Scientific Corp. , posted a net
profit of $135 million, or 39 cents per diluted share, compared
with a profit of $141 million, or 38 cents, a year ago.
Read more at Reuters.com Market News
No comments:
Post a Comment